Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Wall Street Analyst Forum (March 2011)
43 slides from Aethlon Medical's conference presentation, Mar 1, 2011
Slide 1: Wall Street Analyst Forum
aethlon’ @ Wall Street Analyst Forum March 1, 2011
Slide 2: Forward Looking Statements
Forward Looking Statements MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURI
Slide 3: A revolutionary platform technology against infectious disease and cancer
A revolutionary platform technology with broad therapeutic applications against infectious disease and cancer
Slide 4: The Hemopurifier
The Hemopurifier® The first medical device to selectively remove infectious viruses and immunosuppressive toxins from circulation
Slide 5: Dual Benefit of Action
Dual Benefit of Action Simultaneous Antiviral & Immunotherapeutic • Antiviral • Rapid real-time clearance of infectious viral pathogens • Immunotherapeutic • Clearance of virally-shed and cancer-secreted toxins
Slide 6: Our Circle of Opportunity
Hepatitis-C HIV Cancer Biodefense Pandemics Our Circle of Opportunity
Slide 7: Therapeutic Filtration: Beyond Kidney Dialysis
Therapeutic Filtration The Opportunity To Transition Beyond Kidney Dialysis
Slide 8: Market Opportunity
Market Opportunity Application HCV standard of care adjunct HIV drug resistant patients Bioterror & Pandemic Threats broad-spectrum countermeasure CANCER immunotherapy / diagnostic / biomarker
Slide 9: Established global dialysis infrastructure
Our Hemopurifier® has the advantage of being delivered through an established global infrastructure of dialysis stations (90,000+ in U.S. alone)
Slide 10: Additional Infrastructure to Deliver Hemopurifier Therapy
Additional Infrastructure to Deliver Hemopurifier® Therapy Includes: • CRRT machines already located in hospitals and clinics • Portable pump configurations
Slide 11: The Future Home Infectious Disease & Cancer Therapy
The Future Home Infectious Disease & Cancer Therapy
Slide 12: Genesis of our Hemopurifier
Genesis of our Hemopurifier® A 2004 patent submission entitled “A Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis” which issued in 2007
Slide 13: Progress Since 2004
• Broadened our intellectual property portfolio • Completed 11 pre-clinical programs that have validated broad-spectrum effectiveness in capturing infectious viral pathogens • Completed 3 separate human safety studies conducted at the Apollo, Fortis, and Sigma New Life hospitals in India. (68 treatm
Slide 14: What Are Exosomes?
What Are Exosomes?
Slide 15: Exosomes Are Secreted By
Exosomes Are Secreted By: • All solid-form tumors • Lymphomas • Leukemias
Slide 16: Science Publications on Exosomes
Science Publications Indicate That Exosomes • Induce Apoptosis • Disrupt t-cell signaling • Inhibit cytokine production • Angiogenesis • Metastasis
Slide 17: Tumor exosomes
tumor exosomes cytoplasm
Slide 18: Pre-Clinical Hemopurifier Cancer Validations
Pre-Clinical Hemopurifier® Cancer Validations • Ovarian (2008) • Breast (2010) • Colorectal (2010) • Lymphoma (2010) • Melanoma (2010) • Additional Studies (2011)
Slide 19: Our Exosome Therapeutic Opportunity
Our Exosome Therapeutic Opportunity • The Hemopurifier® fills a previously unmet medical need in cancer care • Provides mechanism to preserve immune function • Serves as an adjunct to improve benefit of established and candidate cancer therapies
Slide 20: Aethlon
aethlon! 4
Slide 21: HIV: A Solution to Drug Resistance
Human Immunodeficiency Virus (HIV) A Solution to Drug Resistance
Slide 22: HIV-AIDS Study
HIV-AIDS Study • Infected dialysis patient • 12 treatments / 30 days • 4 hrs per treatment • Performed in absence of drug therapy • Average per treatment viral load reduction of 54% • Improved CD4 t-cell ratios
Slide 23: Bioterrorism & Pandemic Threats
Bioterrorism & Pandemic Threats
Slide 24: Why Return to the Biodefense & Pandemic Threat Space?
Why Return to the Biodefense & Pandemic Threat Space? • HHS is committed to increasing countermeasure support • Focal shift from one-drug-one-bug to broad-spectrum therapies • Countermeasures with commercial market applications now ok • FDA approval not required for stockpile consideration • Non-dil
Slide 25: BARDA Industry Day Presentation
U.S. Department of Health and Human Services BARDA Industry Day Presentation Washington, DC January 12, 2011 James A. Joyce Chairman, CEO
Slide 26: A Broad-Spectrum Antiviral Platform Technology
A Broad-Spectrum Antiviral Platform Technology
Slide 27: New BARDA & PHEMCE Strategic Objectives
The New BARDA & PHEMCE Strategic Objectives • To identify and support the development of innovative broad-spectrum: • Countermeasures • Technologies • Platforms • Strategies that address traditional, enhanced, emerging, and advanced threats
Slide 28: In Vitro Confirmations Against Bioterror and Pandemic Threats
Virus Collaborator Ebola USAMRIID/CDC Dengue NIV/WHO Lassa SFBR West Nile Battelle H5N1 Avian Battelle 1918-r Spanish Flu Battelle 2009 H1N1 Swine Battelle Monkey Pox Battelle In Vitro Confirmations Against Bioterror and Pandemic Threats
Slide 29: Most advanced broad-spectrum countermeasure
The Hemopurifier® represents the most advanced broad-spectrum countermeasure against bioterror and emerging pandemic threats
Slide 30: Ken Alibek quote on Hemopurifier
"The Aethlon Hemopurifier® is the only strategy to address the breadth of pathogens that could be weaponized as agents of bioterrorism." Ken Alibek Director of USSR Bioweapon Program Author of "BIOHAZARD"
Slide 31: Current Activities
Current Activities • Active CRADA with USAMRIID • Defining program opportunities with BARDA • Awaiting a BAA from DTRA • Preparing response to BAA (released on 2/8/11) from DARPA entitled “Dialysis Like Therapeutics”
Slide 32: Hepatitis-C Virus (HCV): Our #1 Priority
Hepatitis-C Virus (HCV) Our #1 Priority
Slide 33: Why HCV?
Why HCV? • 180 million infected • Low response rate to peg-interferon/ribavirin standard of care (SOC) drug therapy • Valuations awarded to organizations with promising adjunct data (Telaprevir from Vertex:VRTX $8.9 bn) • Clinical validation that viral filtration improves HCV cure rates
Slide 34: Advantages of Therapeutic Filtration as an Adjunct to SOC
Advantages of Therapeutic Filtration as an Adjunct to SOC • Improves viral clearance without adding drug toxicity • Improves viral clearance without introducing new drug interaction risks • Provides a mechanism to address all genotypes of HCV • A device has an enduring opportunity to improve benefit
Slide 35: Two therapeutic filtration strategies tested in HCV patients
Two therapeutic filtration strategies have been tested in HCV infected patients • The VRAD, a market approved device from Asahi Kasei Kuraray Medical CO. (Japan) • The Hemopurifier®, a clinical stage device from Aethlon Medical, Inc. (United States)
Slide 36: The Treatment of HCV Genotype-1 Non-Responders
The Treatment of HCV Genotype- 1 Non-Responders
Slide 37: The Hemopurifier vs. VRAD Viral Depletion Analysis
The Hemopurifier® vs. VRAD Viral Depletion Analysis • Average VRAD treatment period of 3 hrs 14 min with benefit of SOC drug therapy (n=72 treatments) • Average Hemopurifier® treatment period of 4 hrs in absence of SOC drug therapy benefit (n=24 treatments)
Slide 38: The Hemopurifier vs. VRAD
The Hemopurifier® vs. VRAD • In addition to improving viral clearance • The Hemopurifier® provides a selective capture mechanism which allows for greater safety and optimization of treatment outcomes • The Hemopurifier® removes immunosuppressive proteins shed by HCV that cannot be addressed by VRAD
Slide 39: The Hemopurifier + SOC?
The Hemopurifier® + SOC? • Initiated clinical study at the Medanta Medicity Institute • Up to 30 patients / up to 6 treatments in first 3 days of SOC • Early clinical endpoints include: • Immediate Virologic Response (IVR) • Rapid Virologic Response (RVR) • Early Virologic Response (EVR) • Commercia
Slide 40: Our foundation to drive shareholder value in 2011
Our foundation to drive shareholder value in 2011 • Positive HCV data • Transition from R&D to revenue generation • Commercialization • Contract-grant income • FDA approval to initiate U.S. clinical programs • New cancer research data • Strategic relationships (infectious disease and cancer)
Slide 41: A revolutionary platform technology against infectious disease and cancer
A revolutionary platform technology with broad therapeutic applications against infectious disease and cancer
Slide 42: San Diego, CA www.AethlonMedical.com
San Diego, CA. 92122 www.AethlonMedical.com
Slide 43: Presenter Information
Presenter Information Jim Joyce Chairman, CEO Aethlon Medical, Inc. (858) 459-7800 x301 jj@aethlonmedical.com
Aethlon Medical — Wall Street Analyst Forum (March 2011) on 6ix